News
-
-
-
REGULATED PRESS RELEASE
NFL Biosciences renforce son Comité Scientifique avec des experts de renommée mondiale pour accompagner le développement en phase 3 de NFL-101, son traitement first in class contre l’addiction au tabac
NFL Biosciences renforce son Comité Scientifique pour accompagner le développement en phase 3 de NFL-101, traitement contre l’addiction au tabac. Expertise internationale et approche innovante -
REGULATED PRESS RELEASE
NFL Biosciences strengthens its scientific committee with world-class experts to support the Phase 3 development of NFL-101, its first-in-class therapy for tobacco addiction
NFL Biosciences strengthens scientific committee with world-class experts for Phase 3 development of NFL-101, a breakthrough therapy for tobacco addiction -
-
PRESS RELEASE
Strongest first quarter in the company's history: JDC achieved consolidated revenue of over EUR 60 million for the first time at the start of the year
JDC Group AG achieves record first-quarter revenue exceeding EUR 60 million. Revenue up by 16.7%. EBITDA increased by 23.9%. Positive outlook for 2025 growth -
PRESS RELEASE
DMS GROUP: FDA CLEARANCE FOR THE !M1 SYSTEM AND THE IMMEDIATE COMMERCIALIZATION IN THE UNITED STATES WITH MEDLINK IMAGING
Diagnostic Medical Systems obtains FDA clearance for commercialization of !M1 mobile radiology solution in the U.S. market, partnering with Medlink Imaging for distribution -
-
-
PRESS RELEASE
PPF announces all-cash offer of EUR 7.00 per share to increase its ProSiebenSat.1 stake up to 29.99%
PPF announces all-cash offer of EUR 7.00 per share to increase ProSiebenSat.1 stake up to 29.99%, providing shareholders with a compelling alternative. Offer enhances strategic shareholding and supports ProSiebenSat.1's transformation
